In this video, Beth Sandy, MSN, CRNP, FAPO, discusses data showing that zongertinib demonstrated manageable safety and promising efficacy in patients with HER2 aberration-positive solid tumors, including those with baseline brain metastases.
Beth Sandy, MSN, CRNP, FAPO Thoracic Oncology Nurse Practitioner Abramson Cancer Center, University of Pennsylvania Philadelphia, PA
Sponsored by
To sign up for our newsletter or print publications, please enter your contact information below.